Clinical Scorecard: HEK293 Cell Line for rAAV Manufacturing
At a Glance
| Category | Detail |
|---|---|
| Condition | Gene therapy development |
| Key Mechanisms | Recombinant adeno-associated virus (rAAV) production |
| Target Population | Patients requiring gene therapies |
| Care Setting | Biotechnology and pharmaceutical manufacturing |
Key Highlights
- NBX1P01 produced a two-fold higher full-to-empty rAAV capsid ratio compared to a leading commercial HEK293 cell line.
- Demonstrated genomic stability over 55 population doubling levels with lower genetic heterogeneity.
- Confirmed more than 70% intact rAAV genomes with minimal encapsidated contaminating DNA.
- Consistent performance across production volumes from 10 mL to 1.5 L.
- Supported multiple rAAV serotypes and clinically relevant transgene sizes.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Broader patient populations as gene therapy programs expand beyond rare diseases.
Quality and consistency in rAAV production are essential for effective gene therapies.
Clinical Best Practices
- Utilize stable and adaptable cell lines for rAAV production.
- Ensure high full-to-empty capsid ratios for quality assurance.
- Monitor genomic stability to reduce variability in manufacturing.
References
- Generation and characterization of a HEK293 cell line optimized for recombinant adeno-associated virus production
- Unlocking Scalable, High-Quality rAAV Production with Xcell™ Eng-HEK293
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
